home / stock / xfor / xfor articles
The FDA approved on Monday X4 Pharmaceuticals Inc’s (NASDAQ:XFOR) Xolremdi (mavorixafor) capsules for use in patients 12 years of age and ...
BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a company driven to improve the lives of people with rare dis...
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene thera...
BOSTON, Nov. 10, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases o...
BOSTON, Oct. 18, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases o...
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases ...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
-7.04% Change Percent:
X4 Pharmaceuticals Inc. Company Name:
XFOR Stock Symbol:
NYSE Market:
X4 Pharmaceuticals Inc. Website:
U.S. launch underway for XOLREMDI™ (mavorixafor) in WHIM syndrome XOLREMDI Phase 3 4WHIM clinical trial data published online in Blood , the journal of the American Society of Hematology Presentation of interim clinical data from the ongoing mavorixafor Phase 2 ...
BOSTON, April 30, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the first quarter ended March 31, 2024 and providing...
The FDA approved on Monday X4 Pharmaceuticals Inc’s (NASDAQ:XFOR) Xolremdi (mavorixafor) capsules for use in patients 12 years of age and ...